» Articles » PMID: 38272952

Analysis of the Longitudinal Stability of Human Plasma MiRNAs and Implications for Disease Biomarkers

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jan 25
PMID 38272952
Authors
Affiliations
Soon will be listed here.
Abstract

There is great interest in developing clinical biomarker assays that can aid in non-invasive diagnosis and/or monitoring of human diseases, such as cancer, cardiovascular disease, and neurological diseases. Yet little is known about the longitudinal stability of miRNAs in human plasma. Here we assessed the intraindividual longitudinal stability of miRNAs in plasma from healthy human adults, and the impact of common factors (e.g., hemolysis, age) that may confound miRNA data. We collected blood by venipuncture biweekly over a 3-month period from 22 research participants who had fasted overnight, isolated total RNA, then performed miRNA qPCR. Filtering and normalization of the qPCR data revealed amplification of 134 miRNAs, 74 of which had high test-retest reliability and low percentage level drift, meaning they were stable in an individual over the 3-month time period. We also determined that, of nuisance factors, hemolysis and tobacco use have the greatest impact on miRNA levels and variance. These findings support that many miRNAs show intraindividual longitudinal stability in plasma from healthy human adults, including some reported as candidate biomarkers for Alzheimer's disease.

Citing Articles

Posterior cingulate cortex microRNA dysregulation differentiates cognitive resilience, mild cognitive impairment, and Alzheimer's disease.

Counts S, Beck J, Maloney B, Malek-Ahmadi M, Ginsberg S, Mufson E Alzheimers Dement. 2025; 21(2):e70019.

PMID: 40008917 PMC: 11863362. DOI: 10.1002/alz.70019.


Review of microRNA detection workflows from liquid biopsy for disease diagnostics.

Naranbat D, Herdes E, Tapinos N, Tripathi A Expert Rev Mol Med. 2025; 27:e11.

PMID: 39911053 PMC: 11879380. DOI: 10.1017/erm.2025.2.


MicroRNA-155 as Biomarker and Its Diagnostic Value in Breast Cancer: A Systematic Review.

Yeo B, Lee W, Mahmud R, Tan G, Wahid M, Cheah Y World J Oncol. 2025; 16(1):1-15.

PMID: 39850528 PMC: 11750751. DOI: 10.14740/wjon1955.


Tumor-derived EV miRNA signatures surpass total EV miRNA in supplementing mammography for precision breast cancer diagnosis.

Kim Y, Kim J, Moon S, Lee H, Lee S, Kim J Theranostics. 2024; 14(17):6587-6604.

PMID: 39479442 PMC: 11519808. DOI: 10.7150/thno.99245.


Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.

Zdralevic M, Radovic A, Raonic J, Popovic N, Klisic A, Vuckovic L Int J Mol Sci. 2024; 25(20).

PMID: 39456841 PMC: 11507567. DOI: 10.3390/ijms252011060.


References
1.
Murillo O, Thistlethwaite W, Rozowsky J, Subramanian S, Lucero R, Shah N . exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. Cell. 2019; 177(2):463-477.e15. PMC: 6616370. DOI: 10.1016/j.cell.2019.02.018. View

2.
Ammerlaan W, Betsou F . Intraindividual Temporal miRNA Variability in Serum, Plasma, and White Blood Cell Subpopulations. Biopreserv Biobank. 2016; 14(5):390-397. DOI: 10.1089/bio.2015.0125. View

3.
Nonaka T, Wong D . Saliva-Exosomics in Cancer: Molecular Characterization of Cancer-Derived Exosomes in Saliva. Enzymes. 2017; 42:125-151. PMC: 6167313. DOI: 10.1016/bs.enz.2017.08.002. View

4.
Diederichs S, Haber D . Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell. 2007; 131(6):1097-108. DOI: 10.1016/j.cell.2007.10.032. View

5.
Quinn J, Patel T, Wong D, Das S, Freedman J, Laurent L . Extracellular RNAs: development as biomarkers of human disease. J Extracell Vesicles. 2015; 4:27495. PMC: 4553262. DOI: 10.3402/jev.v4.27495. View